Heart Failure
We recommend
The impact of age and comorbidities on quality-of-life improvements in patients with chronic heart failure treated with empagliflozin — findings from real-world clinical practice
A sub-analysis of the Emp-Activity study evaluated the impact of age and major comorbidities — type 2 diabetes mellitus and chronic kidney disease — on quality-of-life outcomes in patients with chronic heart failure after initiation of empagliflozin therapy. The findings, presented at the ESC Congress 2026, showed clinically meaningful improvements in most patients across the analysed subgroups, with a slightly greater benefit in patients with type 2 diabetes and a less pronounced improvement in those with chronic kidney disease.
Under the Microscope: How is Patient Care for Heart Failure in the Czech Republic in Real Practice?
The journal Vnitřní lékařství recently published the results of a survey conducted among outpatient…
ACC 2023 Expert Consensus: How to Optimize Diagnosis and Treatment of Heart Failure with Preserved EF LK
Heart failure (HF) remains a significant cause of morbidity and mortality, with the incidence and…
Articles on this topic
Improving treatment outcomes of HF with preserved ejection fraction according to JACC: What does the success of gliflozins mean for the future?
The Journal of the American College of Cardiology (JACC) recently issued a scientific…
Cardio-renal-metabolic syndrome in context
The increase in the incidence of type 2 diabetes mellitus (T2DM), cardiovascular diseases (CVD),...
How Important is the Time Factor in the Treatment of Heart Failure?
Current guidelines emphasize the importance of early diagnosis and immediate treatment for…
The Latest Updates of ESC Recommendations for Heart Failure Treatment
What is new in heart failure therapy? At the annual congress of the European Society of…
Do Gliflozins Affect the Need to Use Diuretics?
Sodium-glucose cotransporter 2 inhibitors (SGLT2i, i.e., gliflozins) have advanced from their…
Efficacy of Empagliflozin in HFpEF Patients – Comparison of Subpopulations with Preserved and Mid-Range LV EF
A sub-analysis of the EMPEROR-Preserved clinical trial examined the effects and safety of…
Analysis of Data from the EMPEROR-Preserved Study Revealed Whether Blood Pressure Affects the Effectiveness of Empagliflozin in Patients with Heart Failure with Preserved Ejection Fraction
Hypertension is among the most common etiological factors of heart failure with preserved…
Empagliflozin will be funded from May for symptomatic heart failure regardless of EF LK value
Empagliflozin entered the market as an antidiabetic drug operating on the principle of…
H₂FPEF Score for Estimating the Probability of Heart Failure with Preserved Ejection Fraction in Persons with Unexplained Dyspnea
The simple, validated H₂FPEF scoring system based on clinical and echocardiographic parameters,...
Diabetes mellitus and heart failure − interconnected units with complex pathogenesis
Diabetes mellitus (DM) represents a significant risk factor for the development of heart…
Prevalence of Heart Failure and Its Subtypes in the Population of Developed Countries
In developed countries, heart failure occurs in approximately 2% of the population, with an…
ESC 2022: Heart Failure with Preserved Ejection Fraction as an Underdiagnosed Problem: How to Increase Its Detection in Everyday Practice?
During this year's European Society of Cardiology Congress (ESC 2022), alarming information…
ESC 2022: SGLT2 Inhibitors as Hope for HFpEF: How to Implement Them in Practice?
Patients with heart failure (HF) can significantly benefit from the inclusion of…
Protective Effect of SGLT2 Inhibitors on Heart Muscle Function - Findings from a Recent Meta-analysis
Sodium-glucose cotransporter 2 inhibitors (SGLT2i, i.e., gliflozins) primarily offer the…
ESC 2022: Evidence of SGLT2i Effectiveness in HFrEF Treatment is Growing: How to Integrate Them into Routine Practice?
Although the need for pharmacotherapeutic options for patients with heart failure with reduced…
Subscribe
E-courses on this topic
Conferences news
Go to records
Most read on this topic
- Empagliflozin Secures Reimbursement for Heart Failure Treatment
- Empagliflozin will be funded from May for symptomatic heart failure regardless of EF LK value
- Cardio-renal-metabolic syndrome in context
- Current Recommendations for Using SGLT2 Inhibitors in Patients with Renal or Cardiovascular Risk
Journal on this topic
Related topic